ArticleRheumatology (Oxford, England)2026
Coronary microvascular dysfunction in systemic sclerosis: insights from PET-derived myocardial flow reserve.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesCardiovascular death is the second leading cause in systemic sclerosis (SSc), with coronary microvascular dysfunction (CMVD) playing a key role. PET-derived myocardial blood flow (MBF) and flow reserve (MFR) offer a validated, non-invasive way to assess CMVD. We studied the prevalence of impaired MFR in SSc and its association with vasodilator or immunomodulatory therapy.
methodsSSc patients who underwent dynamic 82-Rubidium PET myocardial perfusion imaging (MPI) at Yale New Haven Hospital (July 2016 to April 2025) were studied. Patients were matched 3:1 with controls without autoimmune rheumatologic disease based on age, sex, BMI and cardiovascular comorbidities. Abnormal MFR was defined as <2.0.
resultsThe cohort included 67 SSc patients (87% female, age: 61 ± 11 years, 21% diffuse cutaneous SSc, SSc duration: 12 ± 10 years) and 201 controls. Rest MBF was higher in SSc (1.14 [IQR 0.91-1.39] ml/g/min) vs controls (1.00 [IQR 0.78-1.25]; P = 0.01), while MFR was lower (2.17 [IQR 1.84-2.57] vs 2.44 [IQR 1.96-2.96]; P = 0.01). Stress MBF was similar (2.47 [IQR 1.99-2.82] vs 2.43 [IQR 1.91-3.04]; P = 0.85). Multivariable analysis showed MMF use linked to lower odds of abnormal MFR (OR 0.09 [95% CI 0.01-0.56]; P = 0.017), while calcium channel blockers (OR 7.77 [1.93-42.53]; P = 0.008) and statins (OR 7.14 [1.86-36.87]; P = 0.008) increased odds.
conclusionsPET MPI reveals reduced MFR in SSc. Treatment associations, including MMF, should be interpreted cautiously given the retrospective design. PET-derived MFR may serve as a non-invasive marker of vascular involvement, warranting prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.